EHP-101

Research use only, not for human use.

VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.

VCE-004.8 is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. VCE-004.8 attenuates adipogenesis and prevents diet-induced obesity.(In Vivo):In HFD mice, VCE-004.8 (injection; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume, and plasma triglycerides levels. VCE-004.8 can also significantly improve glucose tolerance, reduce leptin levels (a sign of obesity) and increase the levels of adiponectin and glucagon (GLP-1 and GIP) .

——

Etrinabdione (i.p.; 20 mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. Etrinabdione can also significantly ameliorate glucose tolerance, reduce leptin levels (a marker of adiposity) and increase adiponectin and incretins (GLP-1 and GIP) levels.

VCE-004.8

GPCR/G Protein

Cannabinoid Receptor

——

——

——

1818428-24-8

433.592

C28H35NO3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (115.32 mM)

CCCCCC1=C(NCc2ccccc2)C(=O)C([C@@H]2C=C(C)CC[C@H]2C(C)=C)=C(O)C1=O

——

(-20℃)

With Ice Pack

≥ 2 years